EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Incyte's enterprise value is $11,250 Mil.
Incyte's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $407 Mil. Therefore, Incyte's EV-to-EBITDA for today is 27.65.
The historical rank and industry rank for Incyte's EV-to-EBITDA or its related term are showing as below:
INCY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1494.86 Med: 22.71 Max: 2527.51
Current: 27.65
During the past 13 years, the highest EV-to-EBITDA of Incyte was 2527.51. The lowest was -1494.86. And the median was 22.71.
INCY's EV-to-EBITDA is ranked worse than 74.24% of 462
companies
in the Biotechnology industry
Industry Median: 10.615
vs INCY: 27.65
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2025-07-13), Incyte's stock price is $68.59.
Incyte's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $0.320. Therefore, Incyte's PE Ratio (TTM) for today is 214.34.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Incyte EV-to-EBITDA Historical Data
The historical data trend for Incyte's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Incyte's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Incyte's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Incyte's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Incyte's EV-to-EBITDA falls into.
Incyte's current Enterprise Value is $11,250 Mil.
Incyte's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $407 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Incyte (NAS:INCY) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Incyte's share price for today is $68.59.
Incyte's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.320.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Incyte's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INCY has been successfully added to your 